Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Repositioning of the global epicentre of non-optimal cholesterol

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

NCD Risk Factor Collaboration (NCD-RisC) 2020, 'Repositioning of the global epicentre of non-optimal cholesterol', Nature, vol. 582, no. 7810, pp. 73-77. https://doi.org/10.1038/s41586-020-2338-1

APA

CBE

MLA

Vancouver

NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020 Jun 4;582(7810):73-77. https://doi.org/10.1038/s41586-020-2338-1

Author

NCD Risk Factor Collaboration (NCD-RisC). / Repositioning of the global epicentre of non-optimal cholesterol. In: Nature. 2020 ; Vol. 582, No. 7810. pp. 73-77.

Bibtex

@article{157a1ed180b945c0a43f81bbbd735f5e,
title = "Repositioning of the global epicentre of non-optimal cholesterol",
abstract = "High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol-which is a marker of cardiovascular risk-changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million-4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.",
author = "{NCD Risk Factor Collaboration (NCD-RisC)} and Marianne Benn and Anne Tybj{\ae}rg-Hansen and Nordestgaard, {B{\o}rge G.} and Dantoft, {Thomas Meinertz} and {Holm Eliasen}, Marie and Jensen, {Gorm Boje} and Torben J{\o}rgensen and Kamstrup, {Pia R{\o}rb{\ae}k} and Allan Linneberg and M{\o}llehave, {Line Tang} and Thuesen, {Betina Heinsb{\ae}k} and Toft, {Ulla N{\o}rgaard} and Anette Varbo",
note = "Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature Limited. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = jun,
day = "4",
doi = "10.1038/s41586-020-2338-1",
language = "English",
volume = "582",
pages = "73--77",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7810",

}

RIS

TY - JOUR

T1 - Repositioning of the global epicentre of non-optimal cholesterol

AU - NCD Risk Factor Collaboration (NCD-RisC)

A2 - Benn, Marianne

A2 - Tybjærg-Hansen, Anne

A2 - Nordestgaard, Børge G.

A2 - Dantoft, Thomas Meinertz

A2 - Holm Eliasen, Marie

A2 - Jensen, Gorm Boje

A2 - Jørgensen, Torben

A2 - Kamstrup, Pia Rørbæk

A2 - Linneberg, Allan

A2 - Møllehave, Line Tang

A2 - Thuesen, Betina Heinsbæk

A2 - Toft, Ulla Nørgaard

A2 - Varbo, Anette

N1 - Publisher Copyright: © 2020, The Author(s), under exclusive licence to Springer Nature Limited. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/6/4

Y1 - 2020/6/4

N2 - High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol-which is a marker of cardiovascular risk-changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million-4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.

AB - High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol-which is a marker of cardiovascular risk-changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million-4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.

UR - http://www.scopus.com/inward/record.url?scp=85085994877&partnerID=8YFLogxK

U2 - 10.1038/s41586-020-2338-1

DO - 10.1038/s41586-020-2338-1

M3 - Journal article

C2 - 32494083

VL - 582

SP - 73

EP - 77

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7810

ER -

ID: 60005801